Continuous glucose monitoring for the routine care of type 2 diabetes mellitus

• Published in: Nature reviews. Endocrinology Vol. 20; no. 7; p. 426
• Main Authors: Ajjan, Ramzi A, Battelino, Tadej, Cos, Xavier, Del Prato, Stefano, Philips, Jean-Christophe, Meyer, Laurent, Seufert, Jochen, Seidu, Samuel
• Format: Journal Article
• Language: English
• Published: England 01.07.2024
• Subjects: Blood Glucose - analysis; Blood Glucose - metabolism; Blood Glucose Self-Monitoring - methods; Continuous Glucose Monitoring; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Insulin - administration & dosage; Insulin - therapeutic use
• ISSN: 1759-5037
• DOI: 10.1038/s41574-024-00973-1

Although continuous glucose monitoring (CGM) devices are now considered the standard of care for people with type 1 diabetes mellitus, the uptake among people with type 2 diabetes mellitus (T2DM) has been slower and is focused on those receiving intensive insulin therapy. However, increasing evidence now supports the inclusion of CGM in the routine care of people with T2DM who are on basal insulin-only regimens or are managed with other medications. Expanding CGM to these groups could minimize hypoglycaemia while allowing efficient adaptation and escalation of therapies. Increasing evidence from randomized controlled trials and observational studies indicates that CGM is of clinical value in people with T2DM on non-intensive treatment regimens. If further studies confirm this finding, CGM could soon become a part of routine care for T2DM. In this Perspective we explore the potential benefits of widening the application of CGM in T2DM, along with the challenges that must be overcome for the evidence-based benefits of this technology to be delivered for all people with T2DM.